Association of Baseline Frailty with Patient-Reported Outcomes in Systemic Lupus Erythematosus at 1 Year.


Journal

The Journal of frailty & aging
ISSN: 2260-1341
Titre abrégé: J Frailty Aging
Pays: France
ID NLM: 101604797

Informations de publication

Date de publication:
2023
Historique:
medline: 27 7 2023
pubmed: 26 7 2023
entrez: 26 7 2023
Statut: ppublish

Résumé

The relationship of baseline frailty with subsequent patient-reported outcomes in systemic lupus erythematosus (SLE) remains unclear. We assessed these associations in a pilot prospective cohort study. Frailty based on the FRAIL scale and the Fried phenotype and patient-reported outcomes, namely Patient Reported Outcomes Measurement Information System computerized adaptive tests and Valued Life Activities disability, were measured at baseline and 1 year among women aged 18-70 years with SLE enrolled at a single center. Differences in Patient Reported Outcomes Measurement Information System computerized adaptive tests between frail and non-frail participants were evaluated using Wilcoxon rank sum tests, and the association of baseline frailty with self-report disability at 1 year was estimated using linear regression. Of 51 participants, 24% (FRAIL scale) and 16% (Fried phenotype) met criteria for frailty at baseline despite median age of 55.0 and 56.0 years, respectively. Women with (versus without) baseline frailty using either measure had worse 1-year Patient Reported Outcomes Measurement Information System computerized adaptive test scores across multiple domains and greater self-report disability. Baseline frailty was significantly associated with self-report disability at 1 year (FRAIL scale: parameter estimate 0.55, 95% confidence interval (CI) 0.21-0.89, p<0.01; Fried phenotype: parameter estimate 0.61, 95% CI 0.22-1.00, p<0.01), including only slight attenuation after adjustment for SLE cumulative organ damage (FRAIL scale: parameter estimate 0.45, 95% CI 0.09-0.81, p=0.02; Fried phenotype: parameter estimate 0.49, 95% CI 0.09-0.90, p=0.02). These preliminary findings support frailty as an independent risk factor for clinically relevant patient-reported outcomes, including disability onset, among women with SLE.

Identifiants

pubmed: 37493387
doi: 10.14283/jfa.2023.24
pmc: PMC11012234
mid: NIHMS1925789
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

247-251

Subventions

Organisme : NIA NIH HHS
ID : K24 AG053462
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002385
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States

Déclaration de conflit d'intérêts

Dr. Mandl discloses research grants from Regeneron Pharmaceuticals, royalties from UpToDate, and salary support from Annals of Internal Medicine.

Références

J Am Geriatr Soc. 2012 Aug;60(8):1487-92
pubmed: 22881367
Rheumatology (Oxford). 2022 May 5;61(5):1919-1927
pubmed: 34410347
N Engl J Med. 2011 Dec 1;365(22):2110-21
pubmed: 22129255
Lupus. 2020 Jun;29(7):721-726
pubmed: 32323601
Arthritis Rheumatol. 2019 Aug;71(8):1297-1307
pubmed: 30771242
J Rheumatol. 2020 Jan;47(1):72-81
pubmed: 30988130
J Nutr Health Aging. 2012 Jul;16(7):601-8
pubmed: 22836700
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Med Care. 1995 Apr;33(4 Suppl):AS264-79
pubmed: 7723455
Arthritis Rheum. 2007 Aug 15;57(6):972-9
pubmed: 17665467
J Rheumatol. 2022 Jan;49(1):60-67
pubmed: 34470795
Arthritis Care Res (Hoboken). 2023 Mar;75(3):578-584
pubmed: 34590445
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S413-9
pubmed: 22588761
Lupus. 2022 Nov;31(13):1666-1670
pubmed: 36165429
Arthritis Rheum. 2008 Apr 15;59(4):465-73
pubmed: 18383406
N Engl J Med. 2005 Dec 15;353(24):2550-8
pubmed: 16354891
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
J Rheumatol. 2017 Jul;44(7):1024-1031
pubmed: 28412708
Arthritis Care Res (Hoboken). 2022 Apr;74(4):638-647
pubmed: 33152181
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
J Gerontol A Biol Sci Med Sci. 2006 Mar;61(3):262-6
pubmed: 16567375

Auteurs

S B Lieber (SB)

Sarah B. Lieber, MD, MS, Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, Phone (212)606-1935, Fax (212) 606-1519, liebers@hss.edu, ORCID ID: 0000-0002-6176-9740.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH